Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $7 from $6 and keeps a Buy rating on the shares. Paysign’s 261% year-over-year pharma growth was greater-than-expected and the company “remains in the early innings of an earnings inflection driven by pharma’s rapid program growth,” the analyst tells investors in a post-earnings note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue